Marksans Pharma Limited, a Mumbai-headquartered global pharmaceutical company, announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for two key products – Moxonidine 200 microgram Tablets and Moxonidine 400 microgram Tablets.
This regulatory approval strengthens Marksans Pharma’s presence in the UK market and enhances its cardiovascular therapeutic portfolio. Moxonidine is widely prescribed for the treatment of hypertension and is known for its efficacy in managing high blood pressure with a favorable safety profile.
Marksans Pharma is engaged in the research, manufacturing, and marketing of high-quality generic pharmaceutical formulations across global markets. Its manufacturing facilities in India, USA, and UK are approved by leading global regulators, including USFDA, UK MHRA, and Australian TGA. The company’s diversified product portfolio covers multiple therapeutic areas such as cardiovascular system (CVS), central nervous system (CNS), anti-diabetic, gastroenterology, pain management, and anti-allergies.
